Research programme: anti-infectives - Bristol-Myers Squibb

Drug Profile

Research programme: anti-infectives - Bristol-Myers Squibb

Alternative Names: Antibacterials research programme - Bristol-Myers Squibb; Antifungals research programme - Bristol-Myers Squibb; BMS 249524; BMS 411886; BMS 461996; Isoxazolinone antibacterials research programme - Bristol-Myers Squibb; Nocathiacin I

Latest Information Update: 15 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Isoxazoles; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Mycoses

Most Recent Events

  • 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
  • 12 Feb 2004 Genome Therapeutics has merged with GeneSoft Pharmaceuticals
  • 09 May 2001 Preclinical development for Bacterial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top